KALA BIO (KALA) files for 241.44M share offering by selling stockholders Feb 10, 2026 06:04AM
KALA BIO settles $10.6 million debt with $2 million payment Jan 5, 2026 04:10PM
KALA BIO receives $6M investment, appoints new CEO Dec 1, 2025 07:01AM
Mizuho Downgrades Kala Bio (KALA) to Neutral Sep 30, 2025 09:30AM
H.C. Wainwright Downgrades Kala Bio (KALA) to Neutral Sep 29, 2025 01:22PM


Sep 29, 2025 10:57AM LifeSci Capital Downgrades Kala Bio (KALA) to Market Perform
Sep 29, 2025 09:47AM Ladenburg Thalmann Downgrades Kala Bio (KALA) to Neutral
Sep 29, 2025 08:46AM KALA BIO (KALA) Shares Fall 95pct
Sep 29, 2025 08:44AM KALA BIO (KALA) resumes trading, down 95%
Sep 29, 2025 08:43AM Mizuho on KALA BIO (KALA): 'We expect material weakness in the stock today'
Sep 29, 2025 08:06AM KALA BIO fails to meet primary endpoint in corneal defect trial
Sep 8, 2025 05:33AM Mizuho Starts Kala Bio (KALA) at Outperform
Aug 8, 2025 09:29AM KALA BIO (KALA) Misses Q2 EPS by 171c
Jul 9, 2025 08:03AM KALA BIO completes enrollment in CHASE trial for eye disease treatment
Jun 2, 2025 08:53AM Oppenheimer Assumes Kala Bio (KALA) at Outperform
May 23, 2025 06:37AM Kala Bio (KALA) PT Lowered to $12 at H.C. Wainwright
May 14, 2025 04:40PM KALA BIO (KALA) Misses Q1 EPS by 141c
Apr 14, 2025 06:32AM Oppenheimer Reiterates Outperform Rating on Kala Bio (KALA)
Apr 4, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Kala Bio (KALA)
Apr 1, 2025 10:29AM Oppenheimer Reiterates Outperform Rating on Kala Pharmaceuticals (KALA), PT $15
Feb 12, 2025 08:02AM KALA BIO (KALA) Announces Chief Executive Officer Transition
Dec 30, 2024 08:01AM Kala Pharmaceuticals (KALA) Announces $10.75M Private Placement
Nov 18, 2024 07:37AM H.C. Wainwright Reiterates Buy Rating on Kala Pharmaceuticals (KALA)
Aug 7, 2024 06:48AM Kala Pharmaceuticals (KALA) PT Lowered to $15 at H.C. Wainwright
Aug 6, 2024 09:49AM Kala Pharmaceuticals (KALA) Misses Q2 EPS by 316c
Jun 27, 2024 08:01AM Kala Pharmaceuticals (KALA) Announces $12,500,000 Private Placement